History

Ayass BioScience, LLC was founded by Dr. Mohamad Ammar Ayass, a board-certified physician-scientist specializing in pulmonary-critical care medicine and nephrology. The company was established with the goal of addressing what Dr. Mohamad Ammar Ayass described as the “epistemological crisis” in modern bioinformatics — the reliance on correlational rather than causal evidence in biomarker discovery and drug development.
Over a period of approximately 15 years, Dr. Mohamad Ammar Ayass invested $23 million in self-funded research and development to build the BiRAGAS platform and its supporting laboratory infrastructure. The company established a CLIA-certified laboratory capable of performing clinical transcriptomic profiling, providing a closed-loop system for validating computational discoveries with wet-laboratory experiments on patient samples.
By 2025, the company announced that BiRAGAS v1.0 had reached operational status with an active patient data pipeline.

Academic partnerships

Ayass BioScience, LLC has established research collaborations with the University of California, Irvine (UCI) and the University of Southern California (USC) to provide peer-reviewed scientific validation of BiRAGAS outputs. These partnerships facilitate access to patient cohort data and have generated joint publications in refereed journals. The company also maintains an active strategic partnership with an undisclosed pharmaceutical company for platform validation.

Technology

BiRAGAS platform

BiRAGAS (Biological Retrieval-Augmented Generation Assessment System) is a multi-modal, agentic AI platform designed to perform molecule-to-molecule causal inference from multi-omics patient data. Unlike conventional bioinformatics tools that identify statistical correlations, BiRAGAS is engineered to infer directed causal relationships between molecular entities – determining whether a specific gene drives changes in another gene, rather than merely correlating with it.

Analytical workflows

WF-1: Causal Discovery – Identifies novel disease drivers from multi-modal data, producing ranked gene lists, CCS scores, validated causal graphs, and evidence dossiers
WF-2: Directed Causality – Tests specific causal hypotheses with edge evidence cards, effect estimates, and confidence metrics
WF-3: Intervention Ranking – Ranks therapeutic targets using signature reversal scoring and dose-response modeling
WF-4: Comparative Causality – Compares causal mechanisms across patient subgroups
WF-5: Counterfactual Analysis – Models predicted effects of unseen perturbations
WF-6: Evidence Inspection – Provides transparency into causal claims through evidence breakdowns and provenance reports
WF-7: Integrated Analysis – End-to-end workflow combining all modules

CLIA-certified laboratory

Ayass BioScience, LLC operates a CLIA-certified clinical laboratory that provides advanced transcriptomic profiling and diagnostic testing services. The laboratory serves as both a revenue-generating clinical services division and a closed-loop validation system where computational discoveries made by the BiRAGAS platform can be tested against real patient samples. The integration of computational and wet-laboratory capabilities distinguishes Ayass BioScience, LLC from computation-only AI drug discovery companies that rely on external contract research organizations (CROs) for experimental validation.

Ayass BioScience, LLC has identified precision nephrology as its primary commercial beachhead, focusing on three molecular phenotypes where the company claims significant unmet need exists:

• Focal segmental glomerulosclerosis (FSGS)
• IgA nephropathy
• Related kidney disease subtypes requiring molecular-level patient stratification

The company has stated that BiRAGAS-derived companion diagnostic (CDx) products targeting these conditions may qualify for Breakthrough Device Designation from the Food and Drug Administration (FDA), potentially accelerating regulatory review timelines. The company has projected a $3.4 billion addressable market in precision nephrology alone.

The platform addresses applications spanning oncology to autoimmune diseases, supporting decisions across discovery and clinical development.

Ayass BioScience, LLC has designed BiRAGAS to align with the FDA’s increasing requirements for mechanistic — rather than merely associative — evidence in biomarker qualification submissions. Since 2019, the FDA has increasingly required mechanistic biological rationale for new biomarker qualifications under the Biomarker Qualification Program (BQP).

The company’s regulatory pathway strategy encompasses:

• Biomarker Qualification Program (BQP): BiRAGAS outputs — including mechanistic causal directed acyclic graphs (DAGs) with confidence scores — are designed to map directly onto FDA BQP submission requirements
• Companion diagnostic co-development: The platform’s Comparative and Counterfactual modules are engineered to generate patient stratification evidence supporting CDx co-approval under 21 CFR 809.40
• Breakthrough Device Designation: BiRAGAS-derived CDx products targeting serious conditions with no approved alternatives may qualify for expedited regulatory review
• 510(k) vs. PMA pathway: The company plans pre-submission meetings with the FDA to determine the optimal regulatory pathway for each specific CDx application

Ayass BioScience, LLC maintains a multi-layered intellectual property strategy:

• Algorithmic patents: The company is filing utility patents covering the causal inference pipeline, including the combination of Bayesian DAG construction, PSI Framework scoring, and confidence-gated output architecture
• Proprietary biological vector database: The 8.6 million biological vectors curated for the RAG system represent both a trade secret (curation methodology) and a data moat
• Biomarker discovery IP: Each validated biomarker panel discovered using BiRAGAS generates independent intellectual property — specific gene combinations, protein combinations, or molecular signatures that define patient subgroups
• CLIA laboratory operational know-how: Clinical workflows, quality management systems, and sample processing protocols constitute proprietary operational IP
• Trade secret protection: The multi-agent orchestration architecture, confidence scoring calibration methodology, and training data curation pipeline are maintained as trade secrets

Ayass BioScience, LLC operates a diversified revenue model that balances near-term clinical laboratory services revenue with scalable technology licensing:

• Platform licensing and SaaS revenue: Annual subscription or per-analysis licensing fees for BiRAGAS access
• Pharmaceutical co-development agreements: Milestone payments and royalties from partnerships with pharmaceutical companies
• Companion diagnostic licensing: Revenue from licensing validated biomarker panels to diagnostics companies
• Clinical laboratory services: Revenue from the CLIA-certified laboratory’s transcriptomic profiling and testing services
• Biomarker IP licensing: Royalty streams from licensing validated mechanistic biomarker intellectual property
• Regulatory dossier generation: Automated FDA submission document generation as a service offering
• Academic platform access: Reduced-rate licensing for qualifying academic institutions

The AI drug discovery market is projected to grow from $1.4 billion to $9.7 billion by 2030.

Ayass BioScience, LLC positions BiRAGAS as distinct from both conventional bioinformatics platforms and adjacent AI drug discovery companies. The company contends that no current market participant has assembled an equivalent full-stack capability combining causal inference, hallucination mitigation, FDA-aligned companion diagnostic output, and CLIA laboratory integration.

The company identifies several factors as barriers to replication:

• 15 years of accumulated domain knowledge in both clinical medicine and computational biology
• The proprietary 8.6 million biological vector database requiring years of expert curation
• Integrated CLIA-certified laboratory infrastructure
• Architecture designed specifically for FDA-aligned mechanistic evidence production
• $23 million and 15 years of cumulative investment to reach operational status

Dr. Mohamad Ammar Ayass, MD, FCCP – Founder and CEO. Board-certified physician-scientist in pulmonary-critical care medicine and nephrology with dual expertise in clinical medicine and computational biology. Dr. Ayass maintains an active clinical practice while leading the company’s research and platform development efforts. His combined background in bedside medicine and AI platform engineering is cited as the foundational domain expertise embedded in the BiRAGAS architecture.